Article
Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan.
Journal of viral hepatitis - 1 Jul 2003
Huang Y-H, Wu J-C, Chang T-T, Sheen I-J, Lee P-C, Huo T-I, Su C-W, Wang Y-J, Chang F-Y, Lee S-D
Abstract excerpt
The efficacy of lamivudine for HBeAg-negative chronic hepatitis B (CHB) Chinese patients has not been fully investigated. The role of the Hepatitis B virus (HBV) genotype on the treatment effect of lamivudine is controversial. Thirty-two consecutive patients with HBeAg-negative CHB were enrolled. All patients were treated with lamivudine 100 mg once daily of 7-12 months duration. The mean total period of...
Topics
- Adult
- Aged
- Base Sequence
- Cohort Studies
- DNA, Viral
- Female
- Follow-Up Studies
- Genotype
- Hepatitis B e Antigens
- Hepatitis B virus
- Hepatitis B, Chronic